US EditionPublished • loading... • Updated
AstraZeneca Sees Steady Growth Ahead on Strong Cancer Drug Demand
AstraZeneca expects low double-digit profit growth in 2026 driven by a 20% rise in cancer drug sales and major investments in the U.S. and China, the company said.
Summary by Reuters
7 Articles
7 Articles
AstraZeneca sees steady growth ahead on strong cancer drug demand
AstraZeneca forecast steady profit growth in 2026 on Tuesday, banking on strong demand for cancer drugs and new launches to offset patent losses and pricing pressure as it pushes ahead with heavy investments in the U.S. and China.
·United Kingdom
Read Full Article
Merca2.es+2 Reposted by 2 other sources
AstraZeneca closed the year 2025 with a solid economic result and very significant advances in its pipeline, in an environment characterized by intense activity of scientific and regulatory milestones. During the year, total revenues amounted to 58,739 million dollars, representing a growth of 9%, driven mainly by the areas of Oncology, Cardiovascular, Renal and Metabolic (CVRM), Respiratory and Immunology, and Rare Diseases. This growth occurre…
Coverage Details
Total News Sources7
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
